NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Eledon Pharmaceuticals, Inc. ELDN
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.52
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-63.6%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 14-year series below
Revenue
Net income
Per share
USD -0.52
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-63.6%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-26.3%
Each USD of equity lost 64 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 169.0M
total assets, end of FY2025
Total assetsUSD 169.0M
EquityUSD 81.1M
CashUSD 22.8M
Current ratio7.40×
Equity funds 48% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
·
·
·
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
·
·
·
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.52
−0.66
−3.74
−6.16
−2.33
−15.72
−24.42
−1.56
−2.30
−2.46
−2.01
−3.60
−38.02
−31.09
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−63.6
−518.4
·
−93.7
−19.5
−22.8
−133.7
−82.9
−156.6
−14137.5
−84.8
−96.6
·
·
Shares out B
0.08
0.06
0.02
0.01
0.01
0.02
0.00
0.01
0.01
0.00
0.02
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed